Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06881056
NA

Peginterferon α-2b Injection for Aerosol Therapy in Pediatric Respiratory Syncytial Virus Pneumonia

Sponsor: West China Second University Hospital

View on ClinicalTrials.gov

Summary

This is a multicenter, randomized, open-label, parallel-controlled, prospective clinical study. It aims to evaluate the efficacy and safety of aerosolized Peginterferon α-2b injection in the treatment of pediatric respiratory syncytial virus pneumonia. The overall study is divided into a screening period, a treatment period, and a follow-up period. Eligible children with respiratory syncytial virus pneumonia will be randomly assigned to the experimental group 1, experimental group 2, and the control group at a ratio of 1:1:1.

Official title: A Phase 2 Multicenter, Randomized, Open-label Study to Evaluate the Pharmacokinetic, Safety and Efficacy of Peginterferon Alfa-2b Injection in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea.

Key Details

Gender

All

Age Range

1 Year - 3 Years

Study Type

INTERVENTIONAL

Enrollment

90

Start Date

2024-07-17

Completion Date

2026-03-31

Last Updated

2025-03-18

Healthy Volunteers

No

Interventions

DRUG

Peginterferon α-2b injection

Peginterferon α-2b injection, 45 mcg, neb.On the 1st, 3rd, and 5th day, take the medication,while providing symptomatic and supportive treatment simultaneously.

DRUG

Peginterferon α-2b injection

Peginterferon α-2b injection, 90 mcg, neb.On the 1st, 3rd, and 5th day, take the medication,while providing symptomatic and supportive treatment simultaneously.

BEHAVIORAL

symptomatic and supportive treatment

symptomatic and supportive treatment

Locations (2)

Chengdu Women's and Children's Central Hospital

Chengdu, Sichuan, China

West China Second University Hospital of Sichuan University

Chengdu, Sichuan, China